Ibuprofen Market By Type (Tablet, Capsule, Syrup, Injection, Others) , By Application (Rheumatoid Arthritis and Osteoarthritis, Cancer, Pain/Fever/Dysmenorrhea, Inflammatory Diseases, Headache, Others) By Distribution Channel (Hospital pharmacies, Retail Pharmacies, Online Pharmacies) : Global Opportunity Analysis and Industry Forecast, 2024-2033
Ibuprofen Market
The ibuprofen market was valued at $100.0 million in 2023 and is projected to reach $213.6 million by 2033, growing at a CAGR of 7.9% from 2024 to 2033.
Ibuprofen is a nonsteroidal anti-inflammatory drug popular for its efficacy in alleviating pain, reducing inflammation, and lowering fever. It belongs to the analgesics class of medications which are used to ease mild to moderate pain, such as headaches, muscle aches, toothaches, menstrual cramps, and arthritis. The action mechanism of the medication involves inhibiting the production of prostaglandins inside the body, compounds that are the cause of pain and inflammation.
The versatility of ibuprofen in treating several health conditions is a key driver of the market. In addition, ibuprofen witnesses a high demand in several countries where it is accessible as over-the-counter medication, hence contributing to self-medication and elevating the convenience of customers. The market is currently witnessing an emerging trend of de-fossilization of pharmaceuticals. The typical source of formation of ibuprofen is from crude oils. Researchers at the University of Bath have recently discovered a method to develop the medication out of waste generated from the paper manufacturing industry. This discovery marks a significant step by the pharmaceuticals industry toward sustainability.
Despite its benefits, long-term usage of ibuprofen is known to cause severe side-effects such as cardiovascular risks, gastrointestinal complications, and kidney damage. These factors deter several individuals from the consumption of medication, hence restraining the market growth. According to a study posted by the British Medical Journal, ibuprofen is anticipated to elevate the risk of cardiac arrests by 31%. In a similar way, a study published in the Proceedings of the National Academy of Sciences states that high uptake of ibuprofen in young healthy men results in less production of reproductive hormones and occurrence of compensated hypogonadism disorder.
Segment Review
The ibuprofen market is segmented into type, application, distribution channel, and region. On the basis of type, the market is divided into tablet, capsule, syrup, injection, and others. As per application, it is classified into rheumatoid arthritis & osteoarthritis, cancer, pain/fever/dysmenorrhea, inflammatory diseases, headache, and others. Depending on distribution channel, the market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
On the basis of type, the tablet segment dominated the market share in 2023.
As per application, the rheumatoid arthritis segment generated the highest revenue in 2023.
Depending on distribution channel, the hospital pharmacies segment acquired a high market share in 2023.
Region wise, North America is expected to dominate the market by 2033.
Competition Analysis
The major players operating in the global ibuprofen market include Pfizer Inc., Abbott Laboratories Ltd., Solara Active Pharma Sciences Ltd., hndng nhu hrmutl .Ltd, L hml and hrmutl Lmtd, ub u hrmutl .Ltd, trd hrm n Lmtd (hun hrmutl Lmtd), rrg mn l, BASF SE, and Biocause Inc. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.
Key Market Segments
By Type
Tablet
Capsule
Syrup
Injection
Others
By Application
Rheumatoid Arthritis and Osteoarthritis
Cancer
Pain/Fever/Dysmenorrhea
Inflammatory Diseases
Headache
Others
By Distribution Channel
Hospital pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Pfizer Inc.
Abbott Laboratories
Solara Active Pharma Sciences Ltd
BASF SE
Biocause Inc
Shandong Xinhua Pharmaceutical Co Ltd
IOL Chemicals and Pharmaceutical Ltd
Hubei Biocause Pharmaceutical Co Ltd
Strides Pharma Science Ltd
Perrigo Company Plc
- CHAPTER 1: INTRODUCTION
- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits
- 1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3: MARKET LANDSCAPE
- 3.1. Market Definition and Scope
- 3.2. Key Findings
- 3.2.1. Top Investment Pockets
- 3.2.2. Top Winning Strategies
- 3.3. Porter's Five Forces Analysis
- 3.3.1. Bargaining Power of Suppliers
- 3.3.2. Threat of New Entrants
- 3.3.3. Threat of Substitutes
- 3.3.4. Competitive Rivalry
- 3.3.5. Bargaining Power among Buyers
- 3.4. Market Dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities
- CHAPTER 4: IBUPROFEN MARKET, BY TYPE
- 4.1. Market Overview
- 4.1.1 Market Size and Forecast, By Type
- 4.2. Tablet
- 4.2.1. Key Market Trends, Growth Factors and Opportunities
- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
- 4.3. Capsule
- 4.3.1. Key Market Trends, Growth Factors and Opportunities
- 4.3.2. Market Size and Forecast, By Region
- 4.3.3. Market Share Analysis, By Country
- 4.4. Syrup
- 4.4.1. Key Market Trends, Growth Factors and Opportunities
- 4.4.2. Market Size and Forecast, By Region
- 4.4.3. Market Share Analysis, By Country
- 4.5. Injection
- 4.5.1. Key Market Trends, Growth Factors and Opportunities
- 4.5.2. Market Size and Forecast, By Region
- 4.5.3. Market Share Analysis, By Country
- 4.6. Others
- 4.6.1. Key Market Trends, Growth Factors and Opportunities
- 4.6.2. Market Size and Forecast, By Region
- 4.6.3. Market Share Analysis, By Country
- CHAPTER 5: IBUPROFEN MARKET, BY APPLICATION
- 5.1. Market Overview
- 5.1.1 Market Size and Forecast, By Application
- 5.2. Rheumatoid Arthritis And Osteoarthritis
- 5.2.1. Key Market Trends, Growth Factors and Opportunities
- 5.2.2. Market Size and Forecast, By Region
- 5.2.3. Market Share Analysis, By Country
- 5.3. Cancer
- 5.3.1. Key Market Trends, Growth Factors and Opportunities
- 5.3.2. Market Size and Forecast, By Region
- 5.3.3. Market Share Analysis, By Country
- 5.4. Pain/Fever/Dysmenorrhea
- 5.4.1. Key Market Trends, Growth Factors and Opportunities
- 5.4.2. Market Size and Forecast, By Region
- 5.4.3. Market Share Analysis, By Country
- 5.5. Inflammatory Diseases
- 5.5.1. Key Market Trends, Growth Factors and Opportunities
- 5.5.2. Market Size and Forecast, By Region
- 5.5.3. Market Share Analysis, By Country
- 5.6. Headache
- 5.6.1. Key Market Trends, Growth Factors and Opportunities
- 5.6.2. Market Size and Forecast, By Region
- 5.6.3. Market Share Analysis, By Country
- 5.7. Others
- 5.7.1. Key Market Trends, Growth Factors and Opportunities
- 5.7.2. Market Size and Forecast, By Region
- 5.7.3. Market Share Analysis, By Country
- CHAPTER 6: IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL
- 6.1. Market Overview
- 6.1.1 Market Size and Forecast, By Distribution Channel
- 6.2. Hospital Pharmacies
- 6.2.1. Key Market Trends, Growth Factors and Opportunities
- 6.2.2. Market Size and Forecast, By Region
- 6.2.3. Market Share Analysis, By Country
- 6.3. Retail Pharmacies
- 6.3.1. Key Market Trends, Growth Factors and Opportunities
- 6.3.2. Market Size and Forecast, By Region
- 6.3.3. Market Share Analysis, By Country
- 6.4. Online Pharmacies
- 6.4.1. Key Market Trends, Growth Factors and Opportunities
- 6.4.2. Market Size and Forecast, By Region
- 6.4.3. Market Share Analysis, By Country
- CHAPTER 7: IBUPROFEN MARKET, BY REGION
- 7.1. Market Overview
- 7.1.1 Market Size and Forecast, By Region
- 7.2. North America
- 7.2.1. Key Market Trends and Opportunities
- 7.2.2. Market Size and Forecast, By Type
- 7.2.3. Market Size and Forecast, By Application
- 7.2.4. Market Size and Forecast, By Distribution Channel
- 7.2.5. Market Size and Forecast, By Country
- 7.2.6. U.S. Ibuprofen Market
- 7.2.6.1. Market Size and Forecast, By Type
- 7.2.6.2. Market Size and Forecast, By Application
- 7.2.6.3. Market Size and Forecast, By Distribution Channel
- 7.2.7. Canada Ibuprofen Market
- 7.2.7.1. Market Size and Forecast, By Type
- 7.2.7.2. Market Size and Forecast, By Application
- 7.2.7.3. Market Size and Forecast, By Distribution Channel
- 7.2.8. Mexico Ibuprofen Market
- 7.2.8.1. Market Size and Forecast, By Type
- 7.2.8.2. Market Size and Forecast, By Application
- 7.2.8.3. Market Size and Forecast, By Distribution Channel
- 7.3. Europe
- 7.3.1. Key Market Trends and Opportunities
- 7.3.2. Market Size and Forecast, By Type
- 7.3.3. Market Size and Forecast, By Application
- 7.3.4. Market Size and Forecast, By Distribution Channel
- 7.3.5. Market Size and Forecast, By Country
- 7.3.6. Germany Ibuprofen Market
- 7.3.6.1. Market Size and Forecast, By Type
- 7.3.6.2. Market Size and Forecast, By Application
- 7.3.6.3. Market Size and Forecast, By Distribution Channel
- 7.3.7. France Ibuprofen Market
- 7.3.7.1. Market Size and Forecast, By Type
- 7.3.7.2. Market Size and Forecast, By Application
- 7.3.7.3. Market Size and Forecast, By Distribution Channel
- 7.3.8. UK Ibuprofen Market
- 7.3.8.1. Market Size and Forecast, By Type
- 7.3.8.2. Market Size and Forecast, By Application
- 7.3.8.3. Market Size and Forecast, By Distribution Channel
- 7.3.9. Italy Ibuprofen Market
- 7.3.9.1. Market Size and Forecast, By Type
- 7.3.9.2. Market Size and Forecast, By Application
- 7.3.9.3. Market Size and Forecast, By Distribution Channel
- 7.3.10. Spain Ibuprofen Market
- 7.3.10.1. Market Size and Forecast, By Type
- 7.3.10.2. Market Size and Forecast, By Application
- 7.3.10.3. Market Size and Forecast, By Distribution Channel
- 7.3.11. Rest Of Europe Ibuprofen Market
- 7.3.11.1. Market Size and Forecast, By Type
- 7.3.11.2. Market Size and Forecast, By Application
- 7.3.11.3. Market Size and Forecast, By Distribution Channel
- 7.4. Asia-Pacific
- 7.4.1. Key Market Trends and Opportunities
- 7.4.2. Market Size and Forecast, By Type
- 7.4.3. Market Size and Forecast, By Application
- 7.4.4. Market Size and Forecast, By Distribution Channel
- 7.4.5. Market Size and Forecast, By Country
- 7.4.6. Japan Ibuprofen Market
- 7.4.6.1. Market Size and Forecast, By Type
- 7.4.6.2. Market Size and Forecast, By Application
- 7.4.6.3. Market Size and Forecast, By Distribution Channel
- 7.4.7. China Ibuprofen Market
- 7.4.7.1. Market Size and Forecast, By Type
- 7.4.7.2. Market Size and Forecast, By Application
- 7.4.7.3. Market Size and Forecast, By Distribution Channel
- 7.4.8. Australia Ibuprofen Market
- 7.4.8.1. Market Size and Forecast, By Type
- 7.4.8.2. Market Size and Forecast, By Application
- 7.4.8.3. Market Size and Forecast, By Distribution Channel
- 7.4.9. India Ibuprofen Market
- 7.4.9.1. Market Size and Forecast, By Type
- 7.4.9.2. Market Size and Forecast, By Application
- 7.4.9.3. Market Size and Forecast, By Distribution Channel
- 7.4.10. South Korea Ibuprofen Market
- 7.4.10.1. Market Size and Forecast, By Type
- 7.4.10.2. Market Size and Forecast, By Application
- 7.4.10.3. Market Size and Forecast, By Distribution Channel
- 7.4.11. Rest of Asia-Pacific Ibuprofen Market
- 7.4.11.1. Market Size and Forecast, By Type
- 7.4.11.2. Market Size and Forecast, By Application
- 7.4.11.3. Market Size and Forecast, By Distribution Channel
- 7.5. LAMEA
- 7.5.1. Key Market Trends and Opportunities
- 7.5.2. Market Size and Forecast, By Type
- 7.5.3. Market Size and Forecast, By Application
- 7.5.4. Market Size and Forecast, By Distribution Channel
- 7.5.5. Market Size and Forecast, By Country
- 7.5.6. Brazil Ibuprofen Market
- 7.5.6.1. Market Size and Forecast, By Type
- 7.5.6.2. Market Size and Forecast, By Application
- 7.5.6.3. Market Size and Forecast, By Distribution Channel
- 7.5.7. Saudi Arabia Ibuprofen Market
- 7.5.7.1. Market Size and Forecast, By Type
- 7.5.7.2. Market Size and Forecast, By Application
- 7.5.7.3. Market Size and Forecast, By Distribution Channel
- 7.5.8. South Africa Ibuprofen Market
- 7.5.8.1. Market Size and Forecast, By Type
- 7.5.8.2. Market Size and Forecast, By Application
- 7.5.8.3. Market Size and Forecast, By Distribution Channel
- 7.5.9. Rest of LAMEA Ibuprofen Market
- 7.5.9.1. Market Size and Forecast, By Type
- 7.5.9.2. Market Size and Forecast, By Application
- 7.5.9.3. Market Size and Forecast, By Distribution Channel
- CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top Winning Strategies
- 8.3. Product Mapping Of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Top Player Positioning, 2023
- CHAPTER 9: COMPANY PROFILES
- 9.1. Pfizer Inc.
- 9.1.1. Company Overview
- 9.1.2. Key Executives
- 9.1.3. Company Snapshot
- 9.1.4. Operating Business Segments
- 9.1.5. Product Portfolio
- 9.1.6. Business Performance
- 9.1.7. Key Strategic Moves and Developments
- 9.2. Abbott Laboratories
- 9.2.1. Company Overview
- 9.2.2. Key Executives
- 9.2.3. Company Snapshot
- 9.2.4. Operating Business Segments
- 9.2.5. Product Portfolio
- 9.2.6. Business Performance
- 9.2.7. Key Strategic Moves and Developments
- 9.3. Solara Active Pharma Sciences Ltd
- 9.3.1. Company Overview
- 9.3.2. Key Executives
- 9.3.3. Company Snapshot
- 9.3.4. Operating Business Segments
- 9.3.5. Product Portfolio
- 9.3.6. Business Performance
- 9.3.7. Key Strategic Moves and Developments
- 9.4. BASF SE
- 9.4.1. Company Overview
- 9.4.2. Key Executives
- 9.4.3. Company Snapshot
- 9.4.4. Operating Business Segments
- 9.4.5. Product Portfolio
- 9.4.6. Business Performance
- 9.4.7. Key Strategic Moves and Developments
- 9.5. Biocause Inc
- 9.5.1. Company Overview
- 9.5.2. Key Executives
- 9.5.3. Company Snapshot
- 9.5.4. Operating Business Segments
- 9.5.5. Product Portfolio
- 9.5.6. Business Performance
- 9.5.7. Key Strategic Moves and Developments
- 9.6. Shandong Xinhua Pharmaceutical Co Ltd
- 9.6.1. Company Overview
- 9.6.2. Key Executives
- 9.6.3. Company Snapshot
- 9.6.4. Operating Business Segments
- 9.6.5. Product Portfolio
- 9.6.6. Business Performance
- 9.6.7. Key Strategic Moves and Developments
- 9.7. IOL Chemicals And Pharmaceutical Ltd
- 9.7.1. Company Overview
- 9.7.2. Key Executives
- 9.7.3. Company Snapshot
- 9.7.4. Operating Business Segments
- 9.7.5. Product Portfolio
- 9.7.6. Business Performance
- 9.7.7. Key Strategic Moves and Developments
- 9.8. Hubei Biocause Pharmaceutical Co Ltd
- 9.8.1. Company Overview
- 9.8.2. Key Executives
- 9.8.3. Company Snapshot
- 9.8.4. Operating Business Segments
- 9.8.5. Product Portfolio
- 9.8.6. Business Performance
- 9.8.7. Key Strategic Moves and Developments
- 9.9. Strides Pharma Science Ltd
- 9.9.1. Company Overview
- 9.9.2. Key Executives
- 9.9.3. Company Snapshot
- 9.9.4. Operating Business Segments
- 9.9.5. Product Portfolio
- 9.9.6. Business Performance
- 9.9.7. Key Strategic Moves and Developments
- 9.10. Perrigo Company Plc
- 9.10.1. Company Overview
- 9.10.2. Key Executives
- 9.10.3. Company Snapshot
- 9.10.4. Operating Business Segments
- 9.10.5. Product Portfolio
- 9.10.6. Business Performance
- 9.10.7. Key Strategic Moves and Developments
- TABLE 1. GLOBAL IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 2. IBUPROFEN MARKET FOR TABLET, BY REGION, 2024 - 2033 ($MILLION)
- TABLE 3. IBUPROFEN MARKET FOR CAPSULE, BY REGION, 2024 - 2033 ($MILLION)
- TABLE 4. IBUPROFEN MARKET FOR SYRUP, BY REGION, 2024 - 2033 ($MILLION)
- TABLE 5. IBUPROFEN MARKET FOR INJECTION, BY REGION, 2024 - 2033 ($MILLION)
- TABLE 6. IBUPROFEN MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($MILLION)
- TABLE 7. GLOBAL IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 8. IBUPROFEN MARKET FOR RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS, BY REGION, 2024 - 2033 ($MILLION)
- TABLE 9. IBUPROFEN MARKET FOR CANCER, BY REGION, 2024 - 2033 ($MILLION)
- TABLE 10. IBUPROFEN MARKET FOR PAIN/FEVER/DYSMENORRHEA, BY REGION, 2024 - 2033 ($MILLION)
- TABLE 11. IBUPROFEN MARKET FOR INFLAMMATORY DISEASES, BY REGION, 2024 - 2033 ($MILLION)
- TABLE 12. IBUPROFEN MARKET FOR HEADACHE, BY REGION, 2024 - 2033 ($MILLION)
- TABLE 13. IBUPROFEN MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($MILLION)
- TABLE 14. GLOBAL IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 15. IBUPROFEN MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2024 - 2033 ($MILLION)
- TABLE 16. IBUPROFEN MARKET FOR RETAIL PHARMACIES, BY REGION, 2024 - 2033 ($MILLION)
- TABLE 17. IBUPROFEN MARKET FOR ONLINE PHARMACIES, BY REGION, 2024 - 2033 ($MILLION)
- TABLE 18. IBUPROFEN MARKET, BY REGION, 2024 - 2033 ($MILLION)
- TABLE 19. NORTH AMERICA IBUPROFEN MARKET, BY COUNTRY, 2024 - 2033 ($MILLION)
- TABLE 20. NORTH AMERICA IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 21. NORTH AMERICA IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 22. NORTH AMERICA IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 23. U.S. IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 24. U.S. IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 25. U.S. IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 26. CANADA IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 27. CANADA IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 28. CANADA IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 29. MEXICO IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 30. MEXICO IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 31. MEXICO IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 32. EUROPE IBUPROFEN MARKET, BY COUNTRY, 2024 - 2033 ($MILLION)
- TABLE 33. EUROPE IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 34. EUROPE IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 35. EUROPE IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 36. GERMANY IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 37. GERMANY IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 38. GERMANY IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 39. FRANCE IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 40. FRANCE IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 41. FRANCE IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 42. UK IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 43. UK IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 44. UK IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 45. ITALY IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 46. ITALY IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 47. ITALY IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 48. SPAIN IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 49. SPAIN IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 50. SPAIN IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 51. REST OF EUROPE IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 52. REST OF EUROPE IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 53. REST OF EUROPE IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 54. ASIA-PACIFIC IBUPROFEN MARKET, BY COUNTRY, 2024 - 2033 ($MILLION)
- TABLE 55. ASIA-PACIFIC IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 56. ASIA-PACIFIC IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 57. ASIA-PACIFIC IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 58. JAPAN IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 59. JAPAN IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 60. JAPAN IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 61. CHINA IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 62. CHINA IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 63. CHINA IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 64. AUSTRALIA IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 65. AUSTRALIA IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 66. AUSTRALIA IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 67. INDIA IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 68. INDIA IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 69. INDIA IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 70. SOUTH KOREA IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 71. SOUTH KOREA IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 72. SOUTH KOREA IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 73. REST OF ASIA-PACIFIC IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 74. REST OF ASIA-PACIFIC IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 75. REST OF ASIA-PACIFIC IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 76. LAMEA IBUPROFEN MARKET, BY COUNTRY, 2024 - 2033 ($MILLION)
- TABLE 77. LAMEA IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 78. LAMEA IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 79. LAMEA IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 80. BRAZIL IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 81. BRAZIL IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 82. BRAZIL IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 83. SAUDI ARABIA IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 84. SAUDI ARABIA IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 85. SAUDI ARABIA IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 86. SOUTH AFRICA IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 87. SOUTH AFRICA IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 88. SOUTH AFRICA IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 89. REST OF LAMEA IBUPROFEN MARKET, BY TYPE, 2024 - 2033 ($MILLION)
- TABLE 90. REST OF LAMEA IBUPROFEN MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
- TABLE 91. REST OF LAMEA IBUPROFEN MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
- TABLE 92. PFIZER INC.: KEY EXECUTIVES
- TABLE 93. PFIZER INC.: COMPANY SNAPSHOT
- TABLE 94. PFIZER INC.: OPERATING SEGMENTS
- TABLE 95. PFIZER INC.: PRODUCT PORTFOLIO
- TABLE 96. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 97. ABBOTT LABORATORIES: KEY EXECUTIVES
- TABLE 98. ABBOTT LABORATORIES: COMPANY SNAPSHOT
- TABLE 99. ABBOTT LABORATORIES: OPERATING SEGMENTS
- TABLE 100. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
- TABLE 101. ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 102. SOLARA ACTIVE PHARMA SCIENCES LTD: KEY EXECUTIVES
- TABLE 103. SOLARA ACTIVE PHARMA SCIENCES LTD: COMPANY SNAPSHOT
- TABLE 104. SOLARA ACTIVE PHARMA SCIENCES LTD: OPERATING SEGMENTS
- TABLE 105. SOLARA ACTIVE PHARMA SCIENCES LTD: PRODUCT PORTFOLIO
- TABLE 106. SOLARA ACTIVE PHARMA SCIENCES LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 107. BASF SE: KEY EXECUTIVES
- TABLE 108. BASF SE: COMPANY SNAPSHOT
- TABLE 109. BASF SE: OPERATING SEGMENTS
- TABLE 110. BASF SE: PRODUCT PORTFOLIO
- TABLE 111. BASF SE: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 112. BIOCAUSE INC: KEY EXECUTIVES
- TABLE 113. BIOCAUSE INC: COMPANY SNAPSHOT
- TABLE 114. BIOCAUSE INC: OPERATING SEGMENTS
- TABLE 115. BIOCAUSE INC: PRODUCT PORTFOLIO
- TABLE 116. BIOCAUSE INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 117. SHANDONG XINHUA PHARMACEUTICAL CO LTD: KEY EXECUTIVES
- TABLE 118. SHANDONG XINHUA PHARMACEUTICAL CO LTD: COMPANY SNAPSHOT
- TABLE 119. SHANDONG XINHUA PHARMACEUTICAL CO LTD: OPERATING SEGMENTS
- TABLE 120. SHANDONG XINHUA PHARMACEUTICAL CO LTD: PRODUCT PORTFOLIO
- TABLE 121. SHANDONG XINHUA PHARMACEUTICAL CO LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 122. IOL CHEMICALS AND PHARMACEUTICAL LTD: KEY EXECUTIVES
- TABLE 123. IOL CHEMICALS AND PHARMACEUTICAL LTD: COMPANY SNAPSHOT
- TABLE 124. IOL CHEMICALS AND PHARMACEUTICAL LTD: OPERATING SEGMENTS
- TABLE 125. IOL CHEMICALS AND PHARMACEUTICAL LTD: PRODUCT PORTFOLIO
- TABLE 126. IOL CHEMICALS AND PHARMACEUTICAL LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 127. HUBEI BIOCAUSE PHARMACEUTICAL CO LTD: KEY EXECUTIVES
- TABLE 128. HUBEI BIOCAUSE PHARMACEUTICAL CO LTD: COMPANY SNAPSHOT
- TABLE 129. HUBEI BIOCAUSE PHARMACEUTICAL CO LTD: OPERATING SEGMENTS
- TABLE 130. HUBEI BIOCAUSE PHARMACEUTICAL CO LTD: PRODUCT PORTFOLIO
- TABLE 131. HUBEI BIOCAUSE PHARMACEUTICAL CO LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 132. STRIDES PHARMA SCIENCE LTD: KEY EXECUTIVES
- TABLE 133. STRIDES PHARMA SCIENCE LTD: COMPANY SNAPSHOT
- TABLE 134. STRIDES PHARMA SCIENCE LTD: OPERATING SEGMENTS
- TABLE 135. STRIDES PHARMA SCIENCE LTD: PRODUCT PORTFOLIO
- TABLE 136. STRIDES PHARMA SCIENCE LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 137. PERRIGO COMPANY PLC: KEY EXECUTIVES
- TABLE 138. PERRIGO COMPANY PLC: COMPANY SNAPSHOT
- TABLE 139. PERRIGO COMPANY PLC: OPERATING SEGMENTS
- TABLE 140. PERRIGO COMPANY PLC: PRODUCT PORTFOLIO
- TABLE 141. PERRIGO COMPANY PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
- FIGURE 1. GLOBAL IBUPROFEN MARKET, 2024 - 2033
- FIGURE 2. SEGMENTATION OF IBUPROFEN MARKET, 2024 - 2033
- FIGURE 3. TOP INVESTMENT POCKET IN IBUPROFEN MARKET
- FIGURE 4. MODERATE BARGAINING POWER OF BUYERS
- FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS
- FIGURE 6. MODERATE THREAT OF NEW ENTRANTS
- FIGURE 7. LOW THREAT OF SUBSTITUTION
- FIGURE 8. HIGH COMPETITIVE RIVALRY
- FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALIBUPROFEN MARKET
- FIGURE 10. GLOBAL IBUPROFEN MARKET SEGMENTATION, BY TYPE
- FIGURE 11. IBUPROFEN MARKET FOR TABLET, BY COUNTRY, 2024 - 2033 ($MILLION)
- FIGURE 12. IBUPROFEN MARKET FOR CAPSULE, BY COUNTRY, 2024 - 2033 ($MILLION)
- FIGURE 13. IBUPROFEN MARKET FOR SYRUP, BY COUNTRY, 2024 - 2033 ($MILLION)
- FIGURE 14. IBUPROFEN MARKET FOR INJECTION, BY COUNTRY, 2024 - 2033 ($MILLION)
- FIGURE 15. IBUPROFEN MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($MILLION)
- FIGURE 16. GLOBAL IBUPROFEN MARKET SEGMENTATION, BY APPLICATION
- FIGURE 17. IBUPROFEN MARKET FOR RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS, BY COUNTRY, 2024 - 2033 ($MILLION)
- FIGURE 18. IBUPROFEN MARKET FOR CANCER, BY COUNTRY, 2024 - 2033 ($MILLION)
- FIGURE 19. IBUPROFEN MARKET FOR PAIN/FEVER/DYSMENORRHEA, BY COUNTRY, 2024 - 2033 ($MILLION)
- FIGURE 20. IBUPROFEN MARKET FOR INFLAMMATORY DISEASES, BY COUNTRY, 2024 - 2033 ($MILLION)
- FIGURE 21. IBUPROFEN MARKET FOR HEADACHE, BY COUNTRY, 2024 - 2033 ($MILLION)
- FIGURE 22. IBUPROFEN MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($MILLION)
- FIGURE 23. GLOBAL IBUPROFEN MARKET SEGMENTATION, BY DISTRIBUTION CHANNEL
- FIGURE 24. IBUPROFEN MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2024 - 2033 ($MILLION)
- FIGURE 25. IBUPROFEN MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2024 - 2033 ($MILLION)
- FIGURE 26. IBUPROFEN MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2024 - 2033 ($MILLION)
- FIGURE 27. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
- FIGURE 28. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
- FIGURE 29. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
- FIGURE 30. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 31. COMPETITIVE DASHBOARD
- FIGURE 32. COMPETITIVE HEATMAP: IBUPROFEN MARKET
- FIGURE 33. TOP PLAYER POSITIONING, 2023
- FIGURE 34. PFIZER INC.: NET SALES, 2021-2023 ($MILLION)
- FIGURE 35. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 36. PFIZER INC.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 37. ABBOTT LABORATORIES: NET SALES, 2021-2023 ($MILLION)
- FIGURE 38. ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 39. ABBOTT LABORATORIES: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 40. SOLARA ACTIVE PHARMA SCIENCES LTD: NET SALES, 2021-2023 ($MILLION)
- FIGURE 41. SOLARA ACTIVE PHARMA SCIENCES LTD: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 42. SOLARA ACTIVE PHARMA SCIENCES LTD: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 43. BASF SE: NET SALES, 2021-2023 ($MILLION)
- FIGURE 44. BASF SE: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 45. BASF SE: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 46. BIOCAUSE INC: NET SALES, 2021-2023 ($MILLION)
- FIGURE 47. BIOCAUSE INC: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 48. BIOCAUSE INC: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 49. SHANDONG XINHUA PHARMACEUTICAL CO LTD: NET SALES, 2021-2023 ($MILLION)
- FIGURE 50. SHANDONG XINHUA PHARMACEUTICAL CO LTD: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 51. SHANDONG XINHUA PHARMACEUTICAL CO LTD: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 52. IOL CHEMICALS AND PHARMACEUTICAL LTD: NET SALES, 2021-2023 ($MILLION)
- FIGURE 53. IOL CHEMICALS AND PHARMACEUTICAL LTD: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 54. IOL CHEMICALS AND PHARMACEUTICAL LTD: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 55. HUBEI BIOCAUSE PHARMACEUTICAL CO LTD: NET SALES, 2021-2023 ($MILLION)
- FIGURE 56. HUBEI BIOCAUSE PHARMACEUTICAL CO LTD: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 57. HUBEI BIOCAUSE PHARMACEUTICAL CO LTD: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 58. STRIDES PHARMA SCIENCE LTD: NET SALES, 2021-2023 ($MILLION)
- FIGURE 59. STRIDES PHARMA SCIENCE LTD: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 60. STRIDES PHARMA SCIENCE LTD: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 61. PERRIGO COMPANY PLC: NET SALES, 2021-2023 ($MILLION)
- FIGURE 62. PERRIGO COMPANY PLC: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 63. PERRIGO COMPANY PLC: REVENUE SHARE, BY REGION, 2023 (%)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook